Jane Street Group, LLC Viracta Therapeutics, Inc. Transaction History

Jane Street Group, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.89 - $2.13 $12,113 - $28,991	-13,611 Reduced 24.54%	41,854 $59,000
Q1 2023 May 15, 2023	BUY	$1.38 - $2.29 $43,144 - $71,594	31,264 Added 129.18%	55,465 $88,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $30,493 - $106,000	24,201 New	24,201 $35,000

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.